Sunwen Chou, M.D.

  • Professor Emeritus of Medicine, Division of Infectious Diseases, School of Medicine

Education and training

  • Degrees

    • B.A., 1973, Dartmouth College
    • M.D., 1977, UCLA School of Medicine

  • Residency

    • Medicine - UCLA Hospital - (1977-1980)

  • Fellowship

    • Infectious diseases - Stanford University - (1980-1983)

Areas of interest

  • Human cytomegalovirus antivirals and drug resistance

Publications

Elsevier pure profile

Selected publications

  • Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 2008;82:246-53.
  • Chou S, Boivin G, Ives J, Elston R. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J Infect Dis 2014;209:1219-26.
  • Chou S, Ercolani RJ, Sahoo MK, Lefterova MI, Strasfeld LM, Pinsky BA. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother 2014;58:4697-4702.
  • Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother 2015;59:6588-93.
  • Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Research 2017; 148:1-4
  • Chou S, Ercolani RJ, Derakhchan K. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral Research 2018; 157:128-133.
  • Cherrier L, Nasar A Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. American Journal of Transplantation 2018; 18:3060-64.
  • Chou S. Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. Antiviral Research 2020; 172: 104711.
  • Chou S, Song K, Wu J, Bo T, Crumpacker C. Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection. Journal of Infectious Diseases 2022; 226:576-84.
  • Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, Papanicolaou GA, Pereira MR, Wu JJ, Murray RA, Buss NE, Fournier M. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. Journal of Infectious Diseases 2024; 229:413-21.
  • Chou S, Winston DJ, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Gu J, Pocock G, Papanicolaou GA. Comparative emergence of maribavir and ganciclovir resistance in a randomized Phase 3 clinical trial for treatment of cytomegalovirus infection. Journal of Infectious Diseases 2025; 231:e470-7